BioStar Capital

BioStar Capital is a venture capital firm based in Charlevoix, Michigan, founded in 2002 by Louis Cannon. The firm specializes in private equity investments in the medical technology sector, focusing on areas such as medical devices, digital health, robotics, and diagnostics. BioStar Capital places particular emphasis on innovations within cardiovascular and orthopedic medicine. As a Registered Investment Adviser, the firm is dedicated to supporting the growth and development of companies that are advancing healthcare technologies.

Louis Cannon

Founder and Senior Managing Director

Renee Masi

Managing Director

Past deals in Michigan

Amplitude Vascular Systems

Series B in 2023
Amplitude Vascular Systems is a medical device company focused on safely and effectively treating severely calcified arterial disease. It was founded in 2020 and is based in Ann Arbor, Michigan.

Amplitude Vascular Systems

Series B in 2023
Amplitude Vascular Systems is a medical device company focused on safely and effectively treating severely calcified arterial disease. It was founded in 2020 and is based in Ann Arbor, Michigan.

Amplitude Vascular Systems

Venture Round in 2022
Amplitude Vascular Systems is a medical device company focused on safely and effectively treating severely calcified arterial disease. It was founded in 2020 and is based in Ann Arbor, Michigan.

Ablative Solutions

Series D in 2022
Ablative Solutions, Inc. is a clinical-stage medical device company focused on developing innovative treatments for hypertension. Incorporated in 2011 and headquartered in San Jose, California, with an additional office in Kalamazoo, Michigan, the company manufactures the Peregrine System, an endovascular catheter designed for the minimally invasive delivery of diagnostic and therapeutic agents into the perivascular space surrounding peripheral blood vessels. This technology provides a safe and effective alternative to traditional surgical renal denervation, aiming to reduce blood pressure in patients with hypertension that is not well controlled. By using alcohol as a neurolytic agent, Ablative Solutions' infusion catheter may offer significant advantages over energy-based systems, making it a promising option for managing hypertension and related conditions caused by an overactive sympathetic nervous system.

Ablative Solutions

Series D in 2019
Ablative Solutions, Inc. is a clinical-stage medical device company focused on developing innovative treatments for hypertension. Incorporated in 2011 and headquartered in San Jose, California, with an additional office in Kalamazoo, Michigan, the company manufactures the Peregrine System, an endovascular catheter designed for the minimally invasive delivery of diagnostic and therapeutic agents into the perivascular space surrounding peripheral blood vessels. This technology provides a safe and effective alternative to traditional surgical renal denervation, aiming to reduce blood pressure in patients with hypertension that is not well controlled. By using alcohol as a neurolytic agent, Ablative Solutions' infusion catheter may offer significant advantages over energy-based systems, making it a promising option for managing hypertension and related conditions caused by an overactive sympathetic nervous system.

Ablative Solutions

Series B in 2014
Ablative Solutions, Inc. is a clinical-stage medical device company focused on developing innovative treatments for hypertension. Incorporated in 2011 and headquartered in San Jose, California, with an additional office in Kalamazoo, Michigan, the company manufactures the Peregrine System, an endovascular catheter designed for the minimally invasive delivery of diagnostic and therapeutic agents into the perivascular space surrounding peripheral blood vessels. This technology provides a safe and effective alternative to traditional surgical renal denervation, aiming to reduce blood pressure in patients with hypertension that is not well controlled. By using alcohol as a neurolytic agent, Ablative Solutions' infusion catheter may offer significant advantages over energy-based systems, making it a promising option for managing hypertension and related conditions caused by an overactive sympathetic nervous system.

Ablative Solutions

Series A in 2012
Ablative Solutions, Inc. is a clinical-stage medical device company focused on developing innovative treatments for hypertension. Incorporated in 2011 and headquartered in San Jose, California, with an additional office in Kalamazoo, Michigan, the company manufactures the Peregrine System, an endovascular catheter designed for the minimally invasive delivery of diagnostic and therapeutic agents into the perivascular space surrounding peripheral blood vessels. This technology provides a safe and effective alternative to traditional surgical renal denervation, aiming to reduce blood pressure in patients with hypertension that is not well controlled. By using alcohol as a neurolytic agent, Ablative Solutions' infusion catheter may offer significant advantages over energy-based systems, making it a promising option for managing hypertension and related conditions caused by an overactive sympathetic nervous system.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.